Emmy Koeleman
Simon Lewis
Simon Lewis has worked in technology innovation for over 30 years. Currently Director of Product for PitPat – the activity monitor for dogs – he’s previously invented, developed and marketed many technologies that have changed the lives of human users. An engineer by training, but a student of human behaviour by practice, he lives in the stormy intersection of those two worlds, and tries to smooth the waves he finds there.
Pete Richards
Caroline Chan
Caroline Chan is Vice President and General Manager of the 5G Infrastructure Division at Intel Corporation Network Platform Group, responsible for driving Intel global network infrastructure strategy and deliverables for 5G. Caroline leads this organization to identify and develop use cases that incorporate IoT, innovation in wireless technologies, and deployment models like mobile edge computing, alternative spectrums that enabled new service providers and enterprise networks. Since she joined Intel in 2009, Caroline has worked closely with telecom vendors, operators and application developers, driving strategy and marketing in virtualized RAN, mini Cloud RAN and mobile edge computing. Caroline also represents Intel at industry forums. Her research interests include 5G and HetNet performance. Prior to joining Intel, Caroline was Director of Product Management at Nortel Networks where she managed a portfolio of 3G and 4G wireless infrastructure products.
Jonathan J. Gantt
Dr Gerhard Mueller
Gerhard Mueller is Chief Scientific Officer at Gotham Therapeutics, a transatlantic biotech company located in New York City, US, and Munich, Germany, focusing on epitranscriptomic drug discovery. Prior to his appointment at Gotham Therapeutics, he held several research management positions at biotech companies such as Axxima Pharmaceuticals, Munich, and GPC Biotech, Munich and Boston. Most recently, he built from scratch the Medicinal Chemistry business unit at Mercachem, a chemistry service provider in Nijmegen, The Netherlands.
Before his career within the biotech industry, Gerhard held several senior research and project management positions within the pharmaceutical industry, i.e. at Glaxo Group Research in Verona, Italy, at Bayer AG, Leverkusen, Germany, and he headed the medicinal chemistry unit at Organon N.V. in Oss, NL. Gerhard obtained his PhD from the Technical University Munich, under the supervision of Prof. Dr. Horst Kessler establishing the research field of antiadhesive integrin antagonists.
During his career, Gerhard has worked on several disease areas prosecuting different target families, among them protein kinases, proteases, GPCRs, integrins, protein-protein interaction targets and epigenetic enzymes and receptors. From this work, close to 10 clinical candidates emerged, and Gerhard is co-author of more than 75 scientific publications and numerous patents.
Dr Razvan Nutiu
Dr Maria Duca
Dr. Maria Duca is head of the Targeting of Nucleic Acids research group in the Institute of Chemistry of Nice (Université Côte d’Azur - CNRS). After undergraduate studies in Pharmacy and Medicinal Chemistry (Faculty of Pharmacy, Bologna, Italy), she obtained her PhD in Molecular Biochemistry under the supervision of Dr. Paola B. Arimondo (National History Museum, Paris, France), working on topoisomerase II inhibitors targeting specific DNA sequences.
A two-year post-doctoral training in Sydney Hecht’s lab (Departement of Chemistry, University of Virginia, USA) allowed her to pursue the study of nucleic acids/small molecules interactions working on targeted protein mutagenesis upon tRNA chemical modification. After CNRS recruitment as a Research Scientist in 2007, her research activities focus on the targeting of non-coding RNAs using synthetic small molecules toward innovative therapeutic approaches both for anticancer and antimicrobial applications.
